Pegvisomant

培维索孟

Report date: 2024/06/06 13:59:09
First In Class

Base Information

Drug NamePegvisomant
Drug Alias Name培维索孟pegvisomantum派格索曼TrovertSomavert +[7
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionGrowth hormone receptor antagonists
TargetsGrowth hormone receptor
Therapy Area/IndicationsMetabolic SyndromeInsulin ResistanceDiabetes Mellitus +[6
Global Approved IndicationsAcromegaly
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2002/11/12
Country/TerritoryBelgiumUnited StatesEU +[4
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active IndicationsPituitary DiseasesAcromegaly
Inactive IndicationsMetabolic SyndromeInsulin ResistanceDiabetes Mellitus +[4

Other Information

ATC CodeH01AX01